Serious complications · adults with CSOM
1 finding from 1 review
Suspected ototoxicity · adults with CSOM
1 finding from 1 review
Resolution of ear discharge ‐ measured at 1 to 2 weeks · adults with CSOM
It is very uncertain whether topical quinolone changes resolution of ear discharge ‐ 1 to 2 weeks compared with oral amoxicillin‐clavulanic acid combination (very low certainty).
1 finding from 1 review
Resolution of ear discharge ‐ measured after 4 weeks · adults with CSOM
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Health‐related quality of life · adults with CSOM
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Ear pain (otalgia) or discomfort or local irritation · adults with CSOM
1 finding from 1 review
Hearing · adults with CSOM
1 finding from 1 review
Serious complications · adults with CSOM
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Suspected ototoxicity · adults with CSOM
1 finding from 1 review
Resolution of ear discharge ‐ measured at 1 to 2 weeks · adults with CSOM
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Resolution of ear discharge ‐ measured after 4 weeks · adults with CSOM
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Treatment failure · Patients with presumed drug‐sensitive TB
1 finding from 1 review
Relapse · Patients with presumed drug‐sensitive TB
1 finding from 1 review
Death from any cause · Patients with presumed drug‐sensitive TB
It is very uncertain whether fluoroquinolone plus standard regimen changes death from any cause compared with standard regimen alone (very low certainty).
1 finding from 1 review
TB‐related death · Patients with presumed drug‐sensitive TB
It is very uncertain whether fluoroquinolone plus standard regimen changes TB‐related death compared with standard regimen alone (very low certainty).
1 finding from 1 review
Sputum culture conversion at 8 weeks · Patients with presumed drug‐sensitive TB
It is very uncertain whether fluoroquinolone plus standard regimen changes sputum culture conversion at 8 weeks compared with standard regimen alone (very low certainty).
1 finding from 1 review
Serious adverse events · Patients with presumed drug‐sensitive TB
It is very uncertain whether fluoroquinolone plus standard regimen changes serious adverse events compared with standard regimen alone (very low certainty).
1 finding from 1 review
One or more adverse event · Patients with presumed drug‐sensitive TB
It is very uncertain whether fluoroquinolone plus standard regimen changes one or more adverse event compared with standard regimen alone (very low certainty).
1 finding from 1 review
Treatment failure · Patients with presumed drug‐sensitive TB
1 finding from 1 review
Relapse · Patients with presumed drug‐sensitive TB
1 finding from 1 review